UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, Bhatia KP
  • Publication date:
    02/2009
  • Pagination:
    141, 144
  • Journal:
    Journal of Neurology, Neurosurgery and Psychiatry
  • Volume:
    80
  • Issue:
    2
  • Print ISSN:
    0022-3050
  • Keywords:
    activity, Adult, adverse effects, Aged, Alleles, Antiparkinson Agents, article, BRAIN, Brain-Derived Neurotrophic Factor, Corpus Striatum, DISEASE, drug therapy, dyskinesia, Dyskinesia, Drug-Induced, Dyskinesias, etiology, Female, GENE, GENE EXPRESSION, genetics, Genotype, HUMANS, INDUCED DYSKINESIA, Levodopa, LEVODOPA INDUCED DYSKINESIA, Male, METABOLISM, Methods, Middle Aged, Neuronal Plasticity, NEUROTROPHIC FACTOR, ONSET, Parkinson Disease, Parkinson's disease, PATIENT, patients, physiology, PLASTICITY, Polymorphism, Genetic, Receptor, trkB, RELEASE, Risk, Risk Factors, secretion, STRIATUM, Synapses, SYNAPTIC PLASTICITY, TIME, Time Factors, treatment
Abstract
BACKGROUND: Levodopa induced dyskinesias (LID) are a common problem which ultimately limit the effective treatment of patients with Parkinson's disease (PD). There is accumulating evidence that LID develop due to abnormal synaptic plasticity, which is in turn influenced by the release of brain derived neurotrophic factor (BDNF). METHODS: The influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with PD (n = 315), who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated. RESULTS: Patients with the met allele of BDNF, associated with lower activity dependent secretion of BDNF, were at significantly higher risk of developing dyskinesias earlier in the course of treatment with dopaminergic agents (hazard ratio for each additional met allele 2.12, p = 0.001), which persisted following adjustment for potential confounding variables. CONCLUSION: This functional polymorphism may help predict which individuals are most at risk of LID and is consistent with the known actions of BDNF on synaptic plasticity in the striatum
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Clinical and Movement Neurosciences
Author
Clinical and Movement Neurosciences
Author
Clinical and Movement Neurosciences
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by